High-dose inhaled steroids in asthmatics: moderate efficacy gain and suppression of the hypothalamic-pituitary-adrenal (HPA) axis. Research Council of the Norwegian Thoracic Society

We wanted to evaluate the improvement in efficacy when increasing the daily dose of inhaled steroids and to compare the efficacy, safety, and tolerance of 1.6 mg beclomethasone dipropionate (BDP) with that of 2.0 mg fluticasone propionate (FP). The study was a randomized, double-blind, 3 month, multicentre study. One hundred and thirty four asthmatics currently using inhaled steroids (0.4-1.6 mg BDP or budesonide (BUD)) were stratified according to pretrial daily steroid use. Within each stratum they were randomized to either 1.6 mg BDP or 2.0 mg FP. A significant increase in the primary efficacy variables, i.e. mean morning and evening peak expiratory flow (PEF) (approximately 20 l.min-1) during the treatment period, was found for both treatments. No significant differences between the drugs were revealed for these primary or any other secondary efficacy variables (use of beta 2-agonists, symptom scores, and PEF, forced vital capacity (FVC), forced expiratory volume in one second (FEV1) recorded at the clinical visits). However, significant differences between treatments occurred regarding decrease of serum cortisol and adrenocorticotropic hormone. We conclude that, although both treatments gave statistically significant increases in efficacy parameters when compared with baseline, the increases were so small that they can be regarded as being clinically unimportant. Daily doses of BDP, 1.6 mg, and FP, 2.0 mg, had comparable effects on lung function. A suppression of the hypothalamic pituitary adrenal (HPA) axis was only found with a daily dose of 2 mg FP.

This article has been cited by other articles:

				P Mahachoklertwattana, K Sudkronrayudh, C Direkwattanachai, L Choubtum, and C Okascharoen Decreased cortisol response to insulin induced hypoglycaemia in asthmatics treated with inhaled fluticasone propionate Arch. Dis. Child., November 1, 2004; 89(11): 1055 - 1058. [Abstract] [Full Text] [PDF]

				R J Meijer, H A M Kerstjens, L R Arends, H F Kauffman, G H Koëter, and D S Postma Effects of inhaled fluticasone and oral prednisolone on clinical and inflammatory parameters in patients with asthma Thorax, October 1, 1999; 54(10): 894 - 899. [Abstract] [Full Text]

				R. Brus Effects of High-Dose Inhaled Corticosteroids on Plasma Cortisol Concentrations in Healthy Adults Arch Intern Med, September 13, 1999; 159(16): 1903 - 1908. [Abstract] [Full Text] [PDF]

				E. DEROM, J. VAN SCHOOR, W. VERHAEGHE, W. VINCKEN, and R. PAUWELS Systemic Effects of Inhaled Fluticasone Propionate and Budesonide in Adult Patients with Asthma Am. J. Respir. Crit. Care Med., July 1, 1999; 160(1): 157 - 161. [Abstract] [Full Text]

				D. Wales, H. Makker, J. Kane, P. McDowell, and B. R. O'Driscoll Systemic Bioavailability and Potency of High-Dose Inhaled Corticosteroids: A Comparison of Four Inhaler Devices and Three Drugs in Healthy Adult Volunteers Chest, May 1, 1999; 115(5): 1278 - 1284. [Abstract] [Full Text] [PDF]

				J. W. Georgitis The 1997 Asthma Management Guidelines and Therapeutic Issues Relating to the Treatment of Asthma Chest, January 1, 1999; 115(1): 210 - 217. [Abstract] [Full Text] [PDF]

				P. J. BARNES, S. PEDERSEN, and W. W. BUSSE Efficacy and Safety of Inhaled Corticosteroids . New Developments Am. J. Respir. Crit. Care Med., March 1, 1998; 157(3): S1 - 53. [Full Text] [PDF]